Intermittent Fasting for Health & Longevity - Quick Reference Sheet

Intermittent Fasting for Health & Longevity

Created on 08/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Fasting changes when food is eaten, not what. Human evidence supports modest weight and fat loss, steadier blood sugar, better blood fats and blood pressure, and less liver fat — working about as well as eating fewer calories. Longevity claims stay unproven in people. Main downsides: early hunger, muscle loss, and risks for those on medication. (Full Review)

Protocol

Time-Restricted Eating
16:8 or 14:10
All food within an 8–10 hour daily window; most widely used and best tolerated
5:2 Modified Fasting
5 normal, 2 low days
~500–600 kcal on two non-consecutive days weekly
Alternate-Day Fasting
Fast / feed days
~500 kcal or little food on fast days; slight edge for weight loss but harder to sustain
Time to effect
Weight & Blood Sugar
4–12 weeks
Measurable weight loss and blood-sugar improvements appear
Liver & Lipids
Over months
Liver-fat and blood-fat benefits accrue gradually
Fat-Burning & Appetite
Days–2 weeks
Fat-burning and appetite adaptation typically begin

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Type 1 diabetes
  • Current or past eating disorder
  • Underweight (BMI < 18.5)
  • Children and adolescents
  • Frail older adults
  • Advanced kidney or liver disease
Key Interactions
  • Insulin and sulfonylureas (glipizide, glyburide, glimepiride)
  • SGLT2 inhibitors (empagliflozin, dapagliflozin) and metformin
  • Blood-pressure medications (ACE inhibitors, diuretics, beta-blockers)
  • Medications requiring food (NSAIDs, doxycycline, levothyroxine)
  • Warfarin and other narrow-margin drugs
  • Lithium
  • Caffeine, alcohol, and NSAIDs
  • Additive glucose- or pressure-lowering supplements (berberine, chromium, cinnamon extract, high-dose magnesium)
  • Fat-soluble vitamins and minerals (A, D, E, K; iron, magnesium)

Risk & Side Effects

  • High: Hunger, fatigue, and irritability during adaptation; compensatory overeating and reduced diet quality
  • Medium: Loss of lean muscle mass; hypoglycemia in people on glucose-lowering medication; triggering or worsening disordered eating
  • Low: Headaches, constipation, and sleep disturbance; menstrual and hormonal disruption in women; gallstone formation with rapid weight loss
  • Speculative: Cardiovascular risk with very short eating windows; reduced bone mineral density

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks blood-sugar control and fasting response
HbA1c 4.8–5.4% Average blood sugar over ~3 months; key metabolic marker
Fasting insulin 2–5 µIU/mL Detects insulin resistance earlier than glucose
Triglycerides <80 mg/dL Reflects metabolic and lipid response to fasting
HDL cholesterol >55 mg/dL (>60 in women) "Good" cholesterol; cardiovascular protection
LDL cholesterol Context-dependent "Bad" cholesterol; cardiovascular risk
hs-CRP <1.0 mg/L (optimal <0.5) Marker of systemic inflammation
ALT / AST <25 U/L (ALT) Liver enzymes; track fatty-liver improvement
Blood pressure <120/80 mmHg Monitors cardiovascular benefit and over-lowering
Body composition (DEXA) Maintain or increase lean mass Ensures weight lost is fat, not muscle
Electrolytes (sodium, potassium, magnesium) Mid-normal range Guards against depletion during longer fasts

Cadence: Baseline, then ~8–12 weeks, then every 6–12 months; more frequent glucose checks when adjusting diabetes medication.

Qualitative Assessment

  • Energy and focus: stable daytime energy and mental clarity
  • Sleep quality: falling asleep easily and sleeping through the night
  • Hunger and relationship with food: manageable hunger without preoccupation, bingeing, or anxiety around eating
  • Physical performance: maintained strength and exercise capacity
  • Mood and adherence: a sustainable pattern that does not worsen mood or social life